0000950123-21-002146.txt : 20210216 0000950123-21-002146.hdr.sgml : 20210216 20210216061356 ACCESSION NUMBER: 0000950123-21-002146 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 EFFECTIVENESS DATE: 20210216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC CENTRAL INDEX KEY: 0001703031 IRS NUMBER: 813996001 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-18477 FILM NUMBER: 21631918 BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6175162878 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 13F-HR 1 primary_doc.xml 13F-HR LIVE 0001703031 XXXXXXXX 12-31-2020 12-31-2020 false Bain Capital Life Sciences Investors, LLC

200 Clarendon Street Boston MA 02116

13F HOLDINGS REPORT 028-18477 Y Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP and (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P. The shares of common stock of Dynavax Technologies Corporation ("DVAX") included on the Information Table are as reported on Amendment No. 2 to the Schedule 13D filed by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP on May 28, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of DVAX common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding DVAX common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 8,525,000 shares of DVAX common stock.The shares of common stock of Savara Inc ("SVRA") included on the Information Table are as reported on the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 30, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 4,571,139 shares of SVRA common stock.The shares of common stock of X4 Pharmaceuticals, Inc. ("XFOR") included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 9, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of XFOR common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding XFOR common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 1,250,000 shares of XFOR common stock. The shares of common stock of Syros Pharmaceuticals, Inc. ("SYRS" ) included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 14, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SYRS common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SYRS common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 4,000,000 shares of SYRS common stock. Adam Koppel 617-516-2000 /s/ Adam Koppel Boston MA 02-16-2021 5 26 1592801 false 1 28-18476 Bain Capital Life Sciences Partners, LP 2 28-18478 Bain Capital Life Sciences Fund, L.P. 3 28-20270 BC SW, LP 4 Bain Capital Life Sciences Investors II, LLC 5 Bain Capital Life Sciences Fund II, L.P. INFORMATION TABLE 2 2526.xml INFORMATION TABLE FOR FORM 13F DICERNA PHARMACEUTICALS INC COM 253031108 67858 3080237 SH SOLE 3080237 0 0 MARINUS PHARMACEUTICALS INC COM 56854Q101 17459 1431058 SH SOLE 1431058 0 0 SOLID BIOSCIENCES INC COM 83422E105 53517 7060353 SH SOLE 7060353 0 0 APTINYX INC COM 03836N103 30765 8891758 SH SOLE 8891758 0 0 SPRINGWORKS THERAPEUTICS INC COM 85205L107 528040 7281307 SH SOLE 7281307 0 0 DYNAVAX TECHNOLOGIES CORP COM 268158901 48486 10895773 SH SOLE 10895773 0 0 CONSTELLATION PHARMACEUTICALS, INC. COM 210373106 40320 1400000 SH SOLE 1400000 0 0 X4 PHARMACEUTICALS INC COM 98420X103 10600 1648485 SH SOLE 1648485 0 0 SAVARA INC COM 805111101 5898 5128593 SH SOLE 5128593 0 0 ARCUTIS BIOTHERAPEUTICS, INC. COM 03969K108 111937 3979292 SH SOLE 3979292 0 0 MERSANA THERAPEUTICS COM 59045L106 91689 3445667 SH SOLE 3445667 0 0 CRINETICS PHAMACEUTICALS COM 22663K107 15118 1071428 SH SOLE 1071428 0 0 AEGLEA BIO THERAPEUTICS COM 00773J103 21249 2700000 SH SOLE 2700000 0 0 ANNEXON INC COM 03589W102 81138 3241628 SH SOLE 3241628 0 0 NURIX THERAPEUTICS, INC. COM 67080M103 42228 1284314 SH SOLE 1284314 0 0 KYMERA THERAPEUTICS INC. COM 501575104 29735 479605 SH SOLE 479605 0 0 THERAPEUTICS ACQUISITION COR COM CL A 88339T103 13920 1000000 SH SOLE 1000000 0 0 ARYA SCIENCES ACQUISITION CORP III COM CL A G3166W106 10850 1000000 SH SOLE 1000000 0 0 BCTG ACQUISITION CORP COM 05492W103 5720 500000 SH SOLE 500000 0 0 SYROS PHARMACEUTICALS, INC. COM 87184Q107 62768 5785036 SH SOLE 5785036 0 0 ATEA PHARMACEUTICALS, INC. COM 04683R106 234622 5615659 SH SOLE 5615659 0 0 C4 THERAPEUTICS, INC. COM STK 12529R107 54406 1642209 SH SOLE 1642209 0 0 BCLS ACQUISITION CORP COM CL A G0904B105 5431 487500 SH SOLE 487500 0 0 JIYA ACQUISITION CORP COM CL A 47760M102 3090 300000 SH SOLE 300000 0 0 HELIX ACQUISITION CORP COM CL A G4444C102 2843 250000 SH SOLE 250000 0 0 FRAZIER LIFESCIENCES ACQUISITION CORP UNIT 12/09/2025 G3710A121 3114 300000 SH SOLE 300000 0 0